

April 11, 2025

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**  
Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Sub.: Incorporation of a wholly owned subsidiary in France**

**Ref.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Master Circular dated November 11, 2024 ("the SEBI Circular")**

Dear Sir / Madam,

In our earlier intimation dated March 11, 2025, Zydus Lifesciences Limited ("the **Company**") had informed that the Company had entered into a Put Option Agreement, Share Purchase Agreements, and other agreements to acquire, directly or through its affiliates, a controlling stake i.e. 85.6% equity shares ("**Block Acquisition**") of Amplitude Surgical SA, France ("the **Target Entity**") from the existing shareholders at a price of Euro 6.25 per equity share aggregating to a consideration value of Euro 256.8 million.

It was also informed that subject to closing of the Block Acquisition, the Company would file a mandatory simplified cash tender offer for all the remaining shares in the Target Entity, at the same purchase price of Euro 6.25 per equity share of the Target Entity. If the conditions are met at the end of the tender offer, the Company intends to proceed with a compulsory acquisition of the remaining shares from the minority shareholders (squeeze-out) and to delist the Target Entity.

It is decided that the equity shares of the Target Entity will be acquired by a wholly owned subsidiary to be incorporated in France.

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878





We hereby now inform that Zydus MedTech Private Limited, a wholly owned subsidiary of the Company has incorporated a wholly owned subsidiary in the name of Zydus MedTech (France) SAS on April 10, 2025. Zydus MedTech (France) SAS will be acquiring the equity shares of the Target Entity.

Requisite details as required to be disclosed pursuant to the provisions of regulation 30 of the Listing Regulations read with para A of part A of Schedule of the Listing Regulations and para 1.1 of Annexure 18 of the SEBI Circular are provided in **Annexure-“1”**.

Yours faithfully,  
For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Encl.:** As above

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



**Annexure-“1”**

Sr. No.	Particulars	Responses
1.	Name of the target entity, details in brief such as size, turnover etc.:	<p><b>Name of the Entity:</b> Zydus MedTech (France) SAS</p> <p><b>Authorized Share Capital:</b> Euro 1,000</p> <p><b>Paid-up Share Capital:</b> Euro 100</p> <p><b>Turnover:</b> Nil (as Zydus MedTech (France) SAS is yet to commence business operations)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:	<p>Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited has incorporated a wholly owned subsidiary in the name of Zydus MedTech (France) SAS. Hence, Zydus MedTech (France) SAS became a related party.</p> <p>Save and except above, the Promoter / Promoter Group / Group Companies are not interested in the said incorporation.</p>
3.	Industry to which the entity being acquired belongs:	Investment
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>Zydus MedTech (France) SAS is an investment company.</p> <p>The immediate objective of incorporation of Zydus MedTech (France) SAS is to acquire the equity shares of the Target Entity.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not applicable
6.	Indicative time period for completion of the acquisition:	Not applicable

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Sr. No.	Particulars	Responses
7.	Consideration-whether cash consideration or share swap or any other form and details of the same:	100% subscription to the paid-up share capital of Zydus MedTech (France) SAS was in cash.
8.	Cost of acquisition and/or the price at which the shares are acquired:	Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited have subscribed 1,000 equity shares, representing 100% of the paid-up share capital of Zydus MedTech (France) SAS at a total consideration amount of Euro 1,000, including 100 euros of share capital and 900 euros of issuance premium.
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	Zydus MedTech Private Limited, a wholly owned subsidiary holds 100% share capital of Zydus MedTech (France) SAS.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	Zydus MedTech (France) SAS is incorporated in France on April 10, 2025, and is yet to commence its business operations.

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

